In light of the previous studies and the findings of our study, it is evident that there is a discernible advantage to maintaining a higher level of Hb and HCT over time in patients with CKD stages 3–4 to thwart the progress of CKD [including all-cause mortality, ESRD (RRT and eGFR <15 mL/min/1. The gene discussed is GSTM1; the disease is chronic kidney disease.